Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSEMBLE: Long-term Extension Study of Lunsekimig in CRSwNP
NCT06914908Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2025
- Primary completion
- Feb 2029
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of lunsekimig in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Started May 2025; status: active, not recruiting.
02
Drugs
lunsekimig
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06914908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914908.